T1	CHEM 65 77	Tenofovir DP
#1	AnnotatorNotes T1	C3712637; tenofovir diphosphate; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T2	CHEM 393 396	TDF
#2	AnnotatorNotes T2	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T3	ANAT 81 98	células seminales
T4	DISO 235 240	VIH-1
#3	AnnotatorNotes T4	C2363741; HIV-1 infection; Disease or Syndrome
T5	ANAT 113 118	semen
#4	AnnotatorNotes T5	C0036614; Seminal fluid; Body Substance | C2756969; Semen; Body Substance
T6	DISO 132 161	infectados por el virus VIH-1
T7	DISO 288 311	infectados por el VIH-1
#5	AnnotatorNotes T7	C2363741; HIV-1 infection; Disease or Syndrome
T8	CHEM 354 369	antirretroviral
#6	AnnotatorNotes T8	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T9	PROC 454 473	visita de screening
#7	AnnotatorNotes T9	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T10	CHEM 198 201	TAF
T11	CHEM 499 502	RNA
#8	AnnotatorNotes T11	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T12	PROC 593 612	visita de screening
#9	AnnotatorNotes T12	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T13	PROC 616 640	Consentimiento informado
#10	AnnotatorNotes T13	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T14	PROC 750 771	método anticonceptivo
#11	AnnotatorNotes T14	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T15	CHEM 401 404	EVG
#12	AnnotatorNotes T15	C2606637; elvitegravir; Organic Chemical · Pharmacologic Substance
T16	PROC 826 846	visita del screening
#13	AnnotatorNotes T16	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T17	DISO 915 932	Neoplasia maligna
#14	AnnotatorNotes T17	C0006826; Malignant Neoplasms; Neoplastic Process
T18	DISO 947 969	Enfermedad oportunista
T19	CHEM 1023 1049	fármacos antirretrovirales
#15	AnnotatorNotes T19	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T20	DISO 1102 1112	mutaciones
#16	AnnotatorNotes T20	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
T21	CHEM 1115 1124	tenofovir
#17	AnnotatorNotes T21	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T22	DISO 1140 1150	mutaciones
#18	AnnotatorNotes T22	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
T23	CHEM 1168 1176	timidina
#19	AnnotatorNotes T23	C0040077; thymidine; Biologically Active Substance · Nucleic Acid, Nucleoside, or Nucleotide
T24	CHEM 1209 1212	FTC
#20	AnnotatorNotes T24	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T25	CHEM 1341 1349	fármacos
#21	AnnotatorNotes T25	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T26	CHEM 1249 1252	EVG
#22	AnnotatorNotes T26	C2606637; elvitegravir; Organic Chemical · Pharmacologic Substance
T27	DISO 1366 1387	Hepatitis VHB crónica
T28	PROC 1476 1486	bilirubina
T29	DISO 1502 1521	Insuficiencia renal
#23	AnnotatorNotes T29	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T30	CHEM 1555 1565	creatinina
#24	AnnotatorNotes T30	C0010294; creatinine; Biologically Active Substance · Organic Chemical
T31	DISO 1581 1603	Insuficiencia hepática
#25	AnnotatorNotes T31	C0085605; Liver Failure; Disease or Syndrome | C1306571; Hepatic Insufficiency; Pathologic Function
T32	PROC 177 184	régimen
#26	AnnotatorNotes T32	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T33	PROC 346 369	régimen antirretroviral
T34	PROC 477 502	Carga viral del HIV-1 RNA
T35	CHEM 397 400	FTC
#27	AnnotatorNotes T35	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T36	Observation 982 993	Resistencia
#28	AnnotatorNotes T36	C3542449; Drug Resistance Status; Finding
T37	PROC 1454 1457	ALT
#29	AnnotatorNotes T37	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T38	PROC 1460 1463	AST
#30	AnnotatorNotes T38	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T39	ANAT 1516 1521	renal
#31	AnnotatorNotes T39	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T40	PROC 1530 1565	aclaramiento estimado de creatinina
T41	ANAT 1595 1603	hepática
#32	AnnotatorNotes T41	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T42	CHEM 405 409	COBI
#33	AnnotatorNotes T42	C3177235; cobicistat; Organic Chemical · Pharmacologic Substance
T43	CHEM 568 571	TDF
#34	AnnotatorNotes T43	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T44	CHEM 572 575	FTC
#35	AnnotatorNotes T44	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T45	Observation 1299 1310	resistencia
#36	AnnotatorNotes T45	C3542449; Drug Resistance Status; Finding
T46	PROC 503 505	VL
#37	AnnotatorNotes T46	C1261478; Viral load measurement; Laboratory Procedure
T47	CHEM 576 579	EVG
#38	AnnotatorNotes T47	C2606637; elvitegravir; Organic Chemical · Pharmacologic Substance
T48	CHEM 580 584	COBI
#39	AnnotatorNotes T48	C3177235; cobicistat; Organic Chemical · Pharmacologic Substance
T49	Date 13 17	2016
T51	LIVB 122 131	pacientes
#40	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T52	LIVB 150 161	virus VIH-1
#41	AnnotatorNotes T52	C0019704; HIV-1; Virus
T53	LIVB 225 234	Pacientes
#42	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	LIVB 280 287	Hombres
#43	AnnotatorNotes T54	C0025266; Male population group; Population Group
T55	Age 312 321	≥ 18 años
T56	Duration 428 437	≥ 3 meses
T57	Duration 520 548	al menos durante los 6 meses
T58	LIVB 690 698	paciente
#44	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T59	LIVB 721 730	pacientes
#45	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T61	PROC 1075 1084	genotipos
#46	AnnotatorNotes T61	C1285573; Genotype determination; Laboratory Procedure
T62	Neg_cue 1085 1088	sin
T63	Spec_cue 1289 1298	riesgo de
T65	LIVB 1376 1379	VHB
#47	AnnotatorNotes T65	C0019169; hepatitis B virus; Virus
T66	Duration 1380 1387	crónica
#48	AnnotatorNotes T66	C0205191; chronic; Temporal Concept
T68	LIVB 483 488	viral
#49	AnnotatorNotes T68	C0042776; Virus; Virus
T50	LIVB 306 311	VIH-1
#50	AnnotatorNotes T50	C0019704; HIV-1; Virus
T70	LIVB 493 498	HIV-1
#51	AnnotatorNotes T70	C0019704; HIV-1; Virus
T60	DISO 1226 1236	mutaciones
#52	AnnotatorNotes T60	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
T64	Date 933 941	en curso
T67	PROC 1612 1622	Child-Pugh
#53	AnnotatorNotes T67	C3854424; Child-Pugh-Turcotte score; Laboratory Procedure
A1	Assertion T20 Negated
A2	Assertion T45 Speculated
A3	Assertion T22 Negated
A4	Assertion T60 Negated
#54	AnnotatorNotes T6	C2363741; HIV-1 infection; Disease or Syndrome
#55	AnnotatorNotes T33	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
#56	AnnotatorNotes T34	C4764103; HIV-1 RNA Measurement; Laboratory Procedure 
#57	AnnotatorNotes T18	C0029118; Opportunistic Infections; Disease or Syndrome (?)
#58	AnnotatorNotes T27	C0524909; Hepatitis B, Chronic; Disease or Syndrome
#59	AnnotatorNotes T28	C0344395; Bilirubin measurement; Laboratory Procedure 
#60	AnnotatorNotes T40	C1273051; Estimated creatinine clearance; Laboratory Procedure 
R1	Overlap Arg1:T17 Arg2:T64	
R2	Experiences Arg1:T51 Arg2:T6	
R3	Causes Arg1:T52 Arg2:T6	
R4	Experiences Arg1:T51 Arg2:T32	
R5	Used_for Arg1:T10 Arg2:T32	
R6	Experiences Arg1:T53 Arg2:T4	
R7	Experiences Arg1:T54 Arg2:T7	
R8	Has_Age Arg1:T54 Arg2:T55	
R9	Causes Arg1:T50 Arg2:T7	
T69	Result_or_Value 241 250	positivos
#61	AnnotatorNotes T69	C1446409; Positive; Finding
R11	Used_for Arg1:T8 Arg2:T33	
R12	Combined_with Arg1:T2 Arg2:T35	
R13	Combined_with Arg1:T35 Arg2:T15	
R14	Combined_with Arg1:T15 Arg2:T42	
#62	AnnotatorNotes T10	C3713958; tenofovir alafenamide; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T71	Quantifier_or_Qualifier 370 377	estable
#63	AnnotatorNotes T71	C0205360; Stable status; Qualitative Concept
R15	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T71	
R16	Used_for Arg1:T2 Arg2:T33	
R17	Has_Duration_or_Interval Arg1:T8 Arg2:T56	
R18	Has_Duration_or_Interval Arg1:T2 Arg2:T56	
R19	Has_Duration_or_Interval Arg1:T35 Arg2:T56	
R20	Has_Duration_or_Interval Arg1:T15 Arg2:T56	
R21	Has_Duration_or_Interval Arg1:T42 Arg2:T56	
R22	Before Arg1:T33 Arg2:T9	
T72	Quantifier_or_Qualifier 410 427	de forma continua
#64	AnnotatorNotes T72	C0549178; Continuous; Idea or Concept
R23	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T72	
T73	Result_or_Value 506 519	<40 copias/mL
R24	Has_Result_or_Value Arg1:T46 Arg2:T73	
R25	Has_Result_or_Value Arg1:T34 Arg2:T73	
R26	Overlap Arg1:T46 Arg2:T57	
R27	Overlap Arg1:T34 Arg2:T57	
R28	Before Arg1:T34 Arg2:T43	
R29	Before Arg1:T46 Arg2:T43	
R30	Combined_with Arg1:T43 Arg2:T44	
R31	Combined_with Arg1:T44 Arg2:T47	
R32	Combined_with Arg1:T47 Arg2:T48	
R33	Overlap Arg1:T34 Arg2:T12	
R34	Overlap Arg1:T46 Arg2:T12	
T74	CONC 676 685	inclusión
#65	AnnotatorNotes T74	C1512693; Inclusion; Qualitative Concept
R35	Before Arg1:T13 Arg2:T74	
T75	PROC 705 712	estudio
#66	AnnotatorNotes T75	C0008976; Clinical Trials; Research Activity
R36	Before Arg1:T13 Arg2:T75	
R37	Experiences Arg1:T59 Arg2:T14	
T76	Quantifier_or_Qualifier 772 778	eficaz
#67	AnnotatorNotes T76	C1280519; Effectiveness; Qualitative Concept
R38	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T76	
T77	Observation 791 816	relaciones heterosexuales
#68	AnnotatorNotes T77	C0556476; Heterosxual relationship; Finding
R39	Experiences Arg1:T59 Arg2:T77	
R40	Overlap Arg1:T14 Arg2:T77	
R41	After Arg1:T77 Arg2:T16	
T78	PROC 878 885	estudio
R42	Overlap Arg1:T77 Arg2:T78	
R43	After Arg1:T14 Arg2:T16	
R44	Overlap Arg1:T14 Arg2:T78	
#69	AnnotatorNotes T78	C0008976; Clinical Trials; Research Activity
T79	Quantifier_or_Qualifier 970 976	activa
#70	AnnotatorNotes T79	C0679217; Active State; Idea or Concept
R45	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T79	
R46	Overlap Arg1:T36 Arg2:T19	
T80	Quantifier_or_Qualifier 994 1002	primaria
#71	AnnotatorNotes T80	C0205225; Primary; Qualitative Concept
R47	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T80	
R48	Negation Arg1:T62 Arg2:T20	
T81	Quantifier_or_Qualifier 1132 1139	3 o más
A5	Assertion T81 Negated
R49	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T81	
R50	Negation Arg1:T62 Arg2:T81	
R51	Negation Arg1:T62 Arg2:T22	
T82	Quantifier_or_Qualifier 1126 1130	K65R
A6	Assertion T82 Negated
R52	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T82	
T83	Quantifier_or_Qualifier 1195 1199	M41L
A7	Assertion T83 Negated
R53	Negation Arg1:T62 Arg2:T83	
T84	Quantifier_or_Qualifier 1201 1206	L210W
A8	Assertion T84 Negated
R54	Negation Arg1:T62 Arg2:T84	
R55	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T83	
R56	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T84	
T85	Quantifier_or_Qualifier 1214 1221	M184V/I
A9	Assertion T85 Negated
R57	Negation Arg1:T62 Arg2:T85	
T86	Observation 1268 1284	fallo virológico
A10	Status T86 History_of
R58	Negation Arg1:T62 Arg2:T60	
R59	Speculation Arg1:T63 Arg2:T45	
R60	Before Arg1:T86 Arg2:T45	
T87	Quantifier_or_Qualifier 1311 1320	selectiva
R61	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T87	
A11	Assertion T87 Speculated
R62	Overlap Arg1:T36 Arg2:T21	
R63	Overlap Arg1:T36 Arg2:T23	
R64	Overlap Arg1:T36 Arg2:T24	
R65	Overlap Arg1:T36 Arg2:T26	
R66	Overlap Arg1:T36 Arg2:T25	
R67	Overlap Arg1:T45 Arg2:T25	
R68	Overlap Arg1:T19 Arg2:T45	
R69	Overlap Arg1:T21 Arg2:T45	
R70	Overlap Arg1:T23 Arg2:T45	
R71	Overlap Arg1:T24 Arg2:T45	
R72	Overlap Arg1:T26 Arg2:T45	
R73	Causes Arg1:T65 Arg2:T27	
R74	Has_Duration_or_Interval Arg1:T27 Arg2:T66	
T88	Observation 1402 1428	anormalidad de laboratorio
#72	AnnotatorNotes T88	C3648370; laboratory tests nonspecific abnormal findings; Finding
T89	Quantifier_or_Qualifier 1432 1439	Grado 4
R75	Has_Quantifier_or_Qualifier Arg1:T88 Arg2:T89	
T90	Result_or_Value 1487 1496	≥ 1.5xLSN
R76	Has_Result_or_Value Arg1:T28 Arg2:T90	
T91	Result_or_Value 1464 1471	≥ 3xLSN
R77	Has_Result_or_Value Arg1:T38 Arg2:T91	
R78	Has_Result_or_Value Arg1:T37 Arg2:T91	
R81	Location_of Arg1:T39 Arg2:T29	
R82	Location_of Arg1:T41 Arg2:T31	
T92	Result_or_Value 1623 1630	Clase C
R83	Has_Result_or_Value Arg1:T67 Arg2:T92	
T93	Result_or_Value 1566 1575	<50mL/min
R84	Has_Result_or_Value Arg1:T40 Arg2:T93	
T94	Quantifier_or_Qualifier 1522 1528	severa
#73	AnnotatorNotes T94	C1547227; Severe - Severity of Illness Code; Intellectual Product
R85	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T94	
T95	Quantifier_or_Qualifier 1604 1610	severa
#74	AnnotatorNotes T95	C1547227; Severe - Severity of Illness Code; Intellectual Product
R86	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T95	
R10	Has_Result_or_Value Arg1:T4 Arg2:T69	
R87	Experiences Arg1:T59 Arg2:T16	
R88	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T85	
#75	AnnotatorNotes T64	C0521116; Current (present time); Temporal Concept
#76	AnnotatorNotes T86	C4053865; Virologic Non-Response; Finding (?)
A12	Experiencer T51 Patient
A13	Experiencer T53 Patient
A14	Experiencer T54 Patient
A15	Experiencer T58 Patient
A16	Experiencer T59 Patient
